Edoardo Lenci
Pesaro, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Role of Local Treatment to the Prostate in Patients With de Novo Low-volume Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Receptor Pathway Inhibitors.
Journal: European urology open science
Published: March 12, 2026
The impact of relative dose intensity on pathological complete response in neoadjuvant chemotherapy of muscle-invasive urothelial cancer: a multicenter retrospective study.
Journal: The oncologist
Published: February 08, 2026
Immune-based Combinations in Intermediate-/Poor-risk Patients with Non-clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study.
Journal: European urology focus
Published: March 08, 2025
Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study.
Journal: Prostate cancer and prostatic diseases
Published: March 05, 2025
Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study.
Journal: Scientific reports
Published: February 18, 2024
Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study.
Journal: European urology oncology
Published: November 16, 2023
The Impact of Lifestyle Interventions in High-Risk Early Breast Cancer Patients: A Modeling Approach from a Single Institution Experience.
Journal: Cancers
Published: September 28, 2021
Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer.
Journal: Current treatment options in oncology
Published: April 30, 2021
Systemic immune-inflammation index: a prognostic tiebreaker among all in advanced pancreatic cancer.
Systemic immune-inflammation index: a prognostic tiebreaker among all in advanced pancreatic cancer.
Journal: Annals of translational medicine
Published: March 12, 2021
BRCA mutations and gastrointestinal cancers: When to expect the unexpected?
Journal: World journal of clinical oncology
Published: February 27, 2021
The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab.
Journal: Journal of clinical medicine
Published: January 04, 2021
Tumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis.
Journal: Exploration of targeted anti-tumor therapy
Published: January 01, 2021
Last Updated: 09/26/2026